Testing a new antibody treatment for lung blood vessel disease

Plain-English translation of NCT05967299 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

What is this trial?

This is a Phase 1 trial testing a new medication called ZMA001, which is a fully human antibody designed to reduce inflammation and blood vessel changes in the lungs. Researchers are studying whether this medication is safe and how the body processes it when given as a single intravenous infusion. This is the first time this treatment is being tested in humans.

Pulmonary arterial hypertension is a serious condition where blood vessels in the lungs become stiff and narrowed, making it hard for the heart to pump blood through them. Early lab studies suggest this medication might help prevent these dangerous blood vessel changes by reducing harmful inflammation, but doctors need to first confirm it is safe in people.

Do you qualify?

You likely qualify if…

you are between 18 and 60 years old and in good overall health
you are willing to use reliable contraception for 120 days after receiving the infusion (if you can become pregnant) or agree to use a condom for 120 days (if you are a sexually active man)
you have no history of HIV infection
you are able to commit to all study visits and procedures over about 4 months
you have not used tobacco, marijuana, or illicit drugs recently and do not have a history of alcohol abuse

You likely don't qualify if…

you are pregnant, nursing, or planning to become pregnant within 120 days
you have a severe allergy to any ingredient in the study medication or placebo
you have had a recent infection or fever within the past 2 weeks
you have received any other experimental drug in the past month, a live vaccine in the past 6 months, or any vaccine in the past 4 weeks
you have an uncontrolled medical condition that is not responding well to current treatment

What participation looks like

You would receive a single intravenous infusion of either the new medication or placebo (a dummy solution with no active drug), and then return for multiple follow-up visits over about 4 months. Researchers will check your vital signs, draw blood samples at various time points to measure how your body handles the medication, and monitor you carefully for any side effects. Most of your intensive monitoring will happen in the first couple of days after the infusion, with additional visits spread out over the following months.

Testing a new antibody treatment for lung blood vessel disease

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)